Skip to content
Home/Sarah Brennan
sarahbrennan.jpg

Sarah Brennan

Global Commercial Strategy Organization

Sarah Brennan is Company Group Chairman, Global Commercial Strategy Organization, for Johnson & Johnson Innovative Medicine.

In this role, Sarah will be responsible for the global commercial strategy for the Innovative Medicine sector, maximizing the value of our global portfolio and pipeline in close collaboration with R&D, Business Development, the Commercial Regions, and our functional partners. The GCSO teams that will report to Sarah include Global Commercial Therapeutic Areas (Oncology, Immunology, Neuroscience, Cardiovascular Medicine & Pulmonary Hypertension, Retina, and Infectious Diseases & Vaccines); Global Value & Access; Global Commercial Data Science; Global Medical Affairs; and Portfolio Innovation & Commercialization Strategy.

Sarah brings significant breadth and depth of experience across the Innovative Medicine and MedTech sectors, making her well positioned to lead GCSO at this important time. She has led high-performing teams in global and U.S. operating roles in Commercial, R&D, Business Development and Business Transformation. During her most recent role as Head of North America Commercial Strategy & Operations, Sarah demonstrated her ability to further enrich our pipeline and increase the competitiveness of our breakthrough medicines, from launch through LOE, resulting in significant transformation and growth in the region. She also led New Products & Business Development, serving as a strong strategic leader in the assessment of internal and external pipeline opportunities across our therapeutic areas.

Prior to her current role, Sarah was Vice President, Global Business Development for the Cardiovascular, Metabolism & Retina Therapeutic Area, where she was responsible for scientific licensing, acquisitions, transactions, and alliance management, and was instrumental in establishing our Retina portfolio and helping us expand our gene therapy capabilities. Additionally, Sarah made significant contributions to the Infectious Diseases & Vaccines Therapeutic Area during the pandemic, driving global education efforts to build trust in vaccines and, in Neuroscience, led the launch strategy for bapineuzumab for the treatment of Alzheimer’s disease, successfully developing and maintaining a strong alliance partnership with Pfizer.

Sarah began her J&J career in the MedTech sector at Cordis Corporation, where she held positions in clinical research, sales and U.S. and global strategic marketing. She was Worldwide Vice President for Ethicon Biosurgery, where she successfully expanded the portfolio, globalized the business and repositioned biosurgery to become one of our fastest-growing medical device platforms. Over the course of her career, Sarah has mentored countless people and routinely dedicates time to develop talent, including as an active leader in the Women’s Leadership & Inclusion employee resource group.

Sarah received a Bachelor of Science in Biology from Dickinson College in Carlisle, Pennsylvania.